Clinical Research Directory
Browse clinical research sites, groups, and studies.
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Sponsor: John Kirkwood
Summary
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
Official title: Dose-response Analysis of Nivolumab/Relatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participants With Unresectable or Metastatic Melanoma: A Corollary Study of HCC 24-056 (NCT06246916)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2025-11-19
Completion Date
2031-11-01
Last Updated
2025-11-26
Healthy Volunteers
Not specified
Conditions
Interventions
Fianlimab + Cemiplimab
Patients treated with Fianlimab 1600 mg + Cemiplimab 350 mg under protocol NCT06246916
Relatlimab + Nivolumab
Patients treated with Relatlimab 160 mg + Nivolumab 480 mg under protocol NCT06246916
Locations (1)
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States